SPECIALTY GUIDELINE MANAGEMENT

ERIVEDGE (vismodegib)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

B. Compendial Uses

Nodal or distant metastatic basal cell carcinoma

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Basal Cell Carcinoma (BCC)

Authorization of 12 months may be granted for the treatment of locally advanced or metastatic basal cell carcinoma.


III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continuation of therapy for an indication outlined in Section II when there is no evidence of unacceptable toxicity or disease progression on the current regimen.

IV. REFERENCES

- 1. Erivedge [package insert]. South San Francisco, CA: Genentech USA Inc.; January 2019.
- 2. The NCCN Drugs & Biologics Compendium™ © 2018 National Comprehensive Cancer Network, Inc. https://www.nccn.org. Accessed October 24, 2018.
- 3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology® Basal Cell Skin Cancer (Version 1.2019). https://www.nccn.org. Accessed October 24, 2018.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of



© 2019 CVS Caremark. All rights reserved.

